![Luca Santarelli](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profile
Luca Santarelli is the founder.
At VectivBio AG, founded in 2019, the title held is Chief Executive Officer & Director.
At VectivBio Holding AG, founded in 2019, the title held was Chief Executive Officer & Director.
Dr. Santarelli is also the founder of BrainCells, Inc.,Synosia Therapeutics AG,Flexion Therapeutics, Inc.,Therachon AG,Windward Bio AG.
Current jobs include Chairman at Alentis Therapeutics AG since 2023 and Director at Cimeio Therapeutics AG since 2022.
Former jobs include Chief Executive Officer at Therachon SAS, Chief Executive Officer & Member-Supervisory Board at Therachon Holding GmbH from 2016 to 2019, and Senior VP, Head-Neuroscience & Ophthalmology at Roche Holding AG from 2007 to 2015.
Education includes a doctorate from the University of Turin.
Luca Santarelli active positions
| Companies | Position | Start |
|---|---|---|
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology Operates as biotechnology company | Founder | 2018-12-31 |
Alentis Therapeutics AG
 Alentis Therapeutics AG BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapies to treat cancer and reverse fibrosis | Chairman | 2023-06-28 |
Cimeio Therapeutics AG
 Cimeio Therapeutics AG BiotechnologyHealth Technology Operates as a biotechnology company developing shielded-cell & immunotherapy pairs, which protect genetically modified cells from targeted therapies | Director/Board Member | 2022-11-02 |
Former positions of Luca Santarelli
| Companies | Position | End |
|---|---|---|
Therachon AG | Chief Executive Officer | 2021-04-13 |
Therachon Holding GmbH
 Therachon Holding GmbH BiotechnologyHealth Technology Develops medical treatments for rare conditions | Chief Executive Officer | 2019-05-31 |
| ROCHE HOLDING AG | Corporate Officer/Principal | 2015-11-30 |
| FLEXION THERAPEUTICS, INC. | Director of Finance/CFO | - |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of psychiatry and neurology diseases | Founder | - |
Training of Luca Santarelli
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
34
1st degree connections
12
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 12 |
|---|---|
Roche Holding AG
 Roche Holding AG Pharmaceuticals: MajorHealth Technology Operates as a research-focused healthcare company with combined focus in pharmaceuticals and diagnostics | Health Technology |
BrainCells, Inc.
 BrainCells, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs | Health Technology |
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of psychiatry and neurology diseases | Health Technology |
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with musculoskeletal conditions | Health Technology |
University of Turin
 University of Turin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Therachon SAS
 Therachon SAS BiotechnologyHealth Technology Provides biotechnology services | Health Technology |
Therachon Holding GmbH
Therachon Holding GmbH BiotechnologyHealth Technology Develops medical treatments for rare conditions | Health Technology |
Alentis Therapeutics AG
Alentis Therapeutics AG BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapies to treat cancer and reverse fibrosis | Health Technology |
Therachon AG | |
VectivBio Holding AG
 VectivBio Holding AG Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for rare diseases | Health Technology |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology Operates as biotechnology company | Health Technology |
Cimeio Therapeutics AG
Cimeio Therapeutics AG BiotechnologyHealth Technology Operates as a biotechnology company developing shielded-cell & immunotherapy pairs, which protect genetically modified cells from targeted therapies | Health Technology |
- Stock Market
- Insiders
- Luca Santarelli
